Cargando…
Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754724/ https://www.ncbi.nlm.nih.gov/pubmed/32945150 http://dx.doi.org/10.1002/ehf2.12997 |
_version_ | 1783626249073065984 |
---|---|
author | Su, Yang Ma, Teng Wang, Zeyu Dong, Bin Tai, Chenhui Wang, Hao Zhang, Fenglei Yan, Chunxi Chen, Wei Xu, Yawei Ye, Lei Tye, Gee Jun Ong, Sang‐Bing Zhang, Jian Xu, Dachun |
author_facet | Su, Yang Ma, Teng Wang, Zeyu Dong, Bin Tai, Chenhui Wang, Hao Zhang, Fenglei Yan, Chunxi Chen, Wei Xu, Yawei Ye, Lei Tye, Gee Jun Ong, Sang‐Bing Zhang, Jian Xu, Dachun |
author_sort | Su, Yang |
collection | PubMed |
description | AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction using ivabradine improves clinical outcomes in patients with AHF. METHODS AND RESULTS: SHIFT‐AHF is a prospective, multi‐centre, double‐blind, randomized, placebo‐controlled trial to evaluate the efficacy and safety of ivabradine when adding to standard therapy in AHF patients (SHIFT‐AHF). The trial will include 674 AHF patients with left ventricular ejection fraction < 45% and New York Heart Association functional classes III–IV. Participants were enrolled from March 2020 and will be followed up until December 2022. Patients are randomized to treatment with ivabradine or placebo (randomization 1:1). After allocation, the dose of ivabradine is titrated according to HR. Six months' follow‐up and three control visits (7, 90, and 180 days after enrolment) are required for every participant. Assessment involves clinical examination, laboratory tests, echocardiography, electrocardiography, heart rhythm, cardiac function, and quality of life. The primary endpoint is a composite of all‐cause mortality or re‐admission due to worsening HF. Secondary endpoints include the assessments of cardiac remodelling, cardiac functional capacity, and quality of life. CONCLUSIONS: The SHIFT‐AHF trial will shed further light on the role of early HR reduction using ivabradine in patients with AHF. |
format | Online Article Text |
id | pubmed-7754724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77547242020-12-23 Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial Su, Yang Ma, Teng Wang, Zeyu Dong, Bin Tai, Chenhui Wang, Hao Zhang, Fenglei Yan, Chunxi Chen, Wei Xu, Yawei Ye, Lei Tye, Gee Jun Ong, Sang‐Bing Zhang, Jian Xu, Dachun ESC Heart Fail Study Designs AIMS: Elevated heart rate (HR) in heart failure (HF) is associated with worse outcomes, particularly in acute HF (AHF). HR reduction with ivabradine reduces cardiovascular events in HF patients with reduced ejection fraction. The present trial aimed to test the hypothesis that the early HR reduction using ivabradine improves clinical outcomes in patients with AHF. METHODS AND RESULTS: SHIFT‐AHF is a prospective, multi‐centre, double‐blind, randomized, placebo‐controlled trial to evaluate the efficacy and safety of ivabradine when adding to standard therapy in AHF patients (SHIFT‐AHF). The trial will include 674 AHF patients with left ventricular ejection fraction < 45% and New York Heart Association functional classes III–IV. Participants were enrolled from March 2020 and will be followed up until December 2022. Patients are randomized to treatment with ivabradine or placebo (randomization 1:1). After allocation, the dose of ivabradine is titrated according to HR. Six months' follow‐up and three control visits (7, 90, and 180 days after enrolment) are required for every participant. Assessment involves clinical examination, laboratory tests, echocardiography, electrocardiography, heart rhythm, cardiac function, and quality of life. The primary endpoint is a composite of all‐cause mortality or re‐admission due to worsening HF. Secondary endpoints include the assessments of cardiac remodelling, cardiac functional capacity, and quality of life. CONCLUSIONS: The SHIFT‐AHF trial will shed further light on the role of early HR reduction using ivabradine in patients with AHF. John Wiley and Sons Inc. 2020-09-18 /pmc/articles/PMC7754724/ /pubmed/32945150 http://dx.doi.org/10.1002/ehf2.12997 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Study Designs Su, Yang Ma, Teng Wang, Zeyu Dong, Bin Tai, Chenhui Wang, Hao Zhang, Fenglei Yan, Chunxi Chen, Wei Xu, Yawei Ye, Lei Tye, Gee Jun Ong, Sang‐Bing Zhang, Jian Xu, Dachun Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial |
title | Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial |
title_full | Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial |
title_fullStr | Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial |
title_full_unstemmed | Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial |
title_short | Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial |
title_sort | efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of shift‐ahf trial |
topic | Study Designs |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754724/ https://www.ncbi.nlm.nih.gov/pubmed/32945150 http://dx.doi.org/10.1002/ehf2.12997 |
work_keys_str_mv | AT suyang efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT mateng efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT wangzeyu efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT dongbin efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT taichenhui efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT wanghao efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT zhangfenglei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT yanchunxi efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT chenwei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT xuyawei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT yelei efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT tyegeejun efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT ongsangbing efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT zhangjian efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial AT xudachun efficacyofearlyinitiationofivabradinetreatmentinpatientswithacuteheartfailurerationaleanddesignofshiftahftrial |